Search Results - "Toi M"

Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2− advanced breast cancer: final overall survival results of MONARCH 3.

Authors: Goetz, M.P. Toi, M. Huober, J. et al.

Source: Annals of Oncology. Aug2024, Vol. 35 Issue 8, p718-727. 10p.

Corrigendum to "Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2- advanced breast cancer: final overall survival results of MONARCH 3": [Ann Oncol 2024; 35: 718-727].

Authors: Goetz, M.P. Toi, M. Huober, J. et al.

Source: Annals of Oncology. Dec2025, Vol. 36 Issue 12, p1556-1556. 1p.

Lapatinib monotherapy in patients with relapsed, advanced, or metastatic breast cancer: efficacy, safety, and biomarker results from Japanese patients phase II studies.

Authors: Toi, M. Iwata, H. Fujiwara, Y. et al.

Source: British Journal of Cancer. 11/17/2009, Vol. 101 Issue 10, p1676-1682. 7p. 4 Charts, 3 Graphs.

Modulation of thymidine phosphorylase by neoadjuvant chemotherapy in primary breast cancer.

Authors: Toi, M Bando, H Horiguchi, S et al.

Source: British Journal of Cancer. 6/14/2004, Vol. 90 Issue 12, p2338-2343. 6p.

Tissue factor expression in breast cancer tissues: its correlation with prognosis and plasma concentration.

Authors: Ueno, T Toi, M Koike, M et al.

Source: British Journal of Cancer. 7/15/2000, Vol. 83 Issue 2, p164. 7p.

Diagnostic pitfall of D2-40 in adenomatosid tumour.

Authors: Kuroda, N. Toi, M. Hiroi, M. et al.

Source: Histopathology. Nov2007, Vol. 51 Issue 5, p719-721. 3p. 2 Color Photographs.

Evaluation of the nano-beam SIMS apparatus

Authors: Nojima, M. Toi, M. Maekawa, A. et al.

Source: Applied Surface Science. Jun2004, Vol. 231-232, p930-935. 6p.

Subjects: Beam dynamics, Collisions (Nuclear physics), Secondary ion mass spectrometry, Mass spectrometry

Prognostic significance of vascular endothelial growth factor protein in node-negative breast carcinoma.

Authors: Gasparini G Toi M Gion M et al.

Source: JNCI: Journal of the National Cancer Institute. 01/15/97, Vol. 89 Issue 2, p139-147. 9p.

Experimental and Theoretical Analyses on Tilting under Bar and Rod Rolling.

Authors: Asakawa, M. Toi, M. Katayama, Y. et al.

Source: AIP Conference Proceedings. 2004, Vol. 712 Issue 1, p463-468. 6p.

This result is not displayed to guests.
Login for full access.

Thymidine phosphorylase (platelet-derived endothelial-cell growth factor) in cancer biology and treatment.

Authors: Toi M Rahman A Bando H et al.

Source: Lancet Oncology. Mar2005, Vol. 6 Issue 3, p158-166. 9p.

Measurement of an apoptotic product in the sera of breast cancer patients

Authors: Ueno, T. Toi, M. Bivén, K. et al.

Source: European Journal of Cancer. Apr2003, Vol. 39 Issue 6, p769. 6p.

Dynamism of tumour vasculature in the early phase of cancer progression: outcomes from oesophageal cancer research.

Authors: Kumagai Y Toi M Inoue H et al.

Source: Lancet Oncology. Oct2002, Vol. 3 Issue 10, p604-610. 7p.

Visualization of tumor-related blood vessels in human breast by photoacoustic imaging system with a hemispherical detector array.

Authors: Toi, M. Asao, Y. Matsumoto, Y. et al.

Source: Scientific Reports. 2/10/2017, p41970. 1p.

44O Characterization of venous thromboembolic events (VTE), elevated aminotransferases (EAT) and interstitial lung disease (ILD) in monarchE.

Authors: Toi, M. Harbeck, N. Puig, J.M. et al.

Source: Annals of Oncology. 2021 Supplement 2, Vol. 32, pS39-S40. 2p.

45O Abemaciclib plus fulvestrant in East Asian women with HR+, HER2- advanced breast cancer: Overall survival from MONARCH 2.

Authors: Huang, C-S. Toi, M. Im, Y-H. et al.

Source: Annals of Oncology. 2020 Supplement 6, Vol. 31, pS1258-S1259. 2p.

This result is not displayed to guests.
Login for full access.

LBA15 MONARCH 3: Interim overall survival (OS) results of abemaciclib plus a nonsteroidal aromatase inhibitor (NSAI) in patients (pts) with HR+, HER2- advanced breast cancer (ABC).

Authors: Goetz, M.P. Toi, M. Huober, J. et al.

Source: Annals of Oncology. 2022 Supplement 7, Vol. 33, pS1384-S1384. 1p.

Long-term outcomes of aromatase inhibition for breast cancer.

Authors: Toi M (AUTHOR)

Source: Lancet Oncology. Jan2008, Vol. 9 Issue 1, p8-10. 3p.

Trastuzumab Deruxtecan plus Pertuzumab for HER2-Positive Metastatic Breast Cancer.

Authors: Tolaney, S. M. Jiang, Z. Zhang, Q. et al.

Source: New England Journal of Medicine. 2/5/2026, Vol. 394 Issue 6, p551-562. 12p.